Systematic review of therapy for men with overactive bladder
DOI:
https://doi.org/10.5489/cuaj.714Abstract
Lower urinary tract symptoms (LUTS) can have multiple causes inmen. Overactive bladder (OAB) is an empirical diagnosis used as
the basis for initial management after assessing symptoms, physical
findings, urinalysis and other indicated evaluations. In men,
the diagnosis is complicated by the potential of benign prostatic
hyperplasia (BPH), which is a histological diagnosis. Although
storage symptoms (i.e., those associated with OAB) are the most
bothersome group of LUTS in men with BPH, these patients are
usually treated with BPH rather than OAB drugs. The standard
pharmacologic treatment of patients with bothersome voiding and
storage LUTS at low risk of progression should be an α1-AR antagonist.
The combination α1-AR antagonist + antimuscarinic agent
is an appropriate and valid option for male patients with voiding
symptoms and persistent storage symptoms.
Downloads
Downloads
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.